Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma - Case report

Neurologia Medico-Chirurgica

Volumn 47, Issue 5, 2007, Pages 229-232

  Makino, Keishi ^a   Nakamura, Hideo ^a   Kudo, Mareina ^a   Takeshima, Hideo ^a   Kuratsu, Jun Ichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Elderly; Primary central nervous system lymphoma; Recurrence; Rituximab; Temozolomide

Indexed keywords

METHOTREXATE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM LYMPHOMA; DISORIENTATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL ACTIVITY; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR VOLUME;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; HUMANS; LYMPHOMA, B-CELL; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 34249667690     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.47.229     Document Type: Article

References (26)

1. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859-863, 1998
2. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144-3150, 2000
3. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137-5144, 2001
4. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709-723, 2001
5. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21: 1044-1049, 2003
6. DeAngelis LM: Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 43: 249-257, 1999
7. DeAngelis LM, Yahalom J, Thaler HT, Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635-643, 1992
8. Ferreri AJ, Reni M, Villa E: Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 11: 927-937, 2000
9. Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML: Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 30: 257-265, 1996
10. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH: Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259-268, 1999
11. Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M: PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54: 1707-1708, 2000
12. Herrlinger U, Kuker W, Platten M, Dichgans J, Weller M: First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58: 1573-1574, 2002
13. Lerro KA, Lacy J: Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 59: 165-168, 2002
14. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997
15. Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 29: 2-9, 2002
16. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 42: 433-440, 1998
17. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46: 51-61, 2000
18. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998
19. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9-17, 1992
20. Plotkin SR, Batchelor TT: Advances in the therapy of primary central nervous system lymphoma. Clin Lymphoma 1: 263-277, 2001
21. Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63: 939-947, 1989
22. Reni M, Ferreri AJ: Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80 Suppl 3: B113-117, 2001
23. Reni M, Ferreri AJ, Landoni C, Villa E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92: 575-576, 2000
24. Reni M, Ferreri AJ, Villa E: Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79: 530-534, 1999
25. Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40: 1682-1688, 2004
26. Wong ET, Tishler R, Barron L, Wu JK: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101: 139-145, 2004